Latest Lung Cancer News | NSCLC/SCLC Treatment Information

Lung Cancers News

LUNG CANCER ADVISOR

Lung Cancers News

A Growing Focus on Rare Cancers in Phase I Trials

This study was presented at the 2019 International Congress on Targeted Anticancer Therapies (TAT) in Paris, France, from February 25-27, 2019. Dr Jun Sato of the National Cancer Center Hospital, Japan is the lead author of this study.1 Results from a retrospective study evaluating the focus of early-phase clinical trials of investigational drug candidates in…
FDA_drug approval

Tecentriq Combination Regimen Approved for Metastatic Non-Squamous NSCLC

The approval was based on data from the IMpower 150 trial, an open-label study involving 1202 patients with stage IV metastatic NSq NSCLC who had not received prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene status and ECOG performance status 0 or 1.
Next post in Lung Cancer